

Takeda inks pact to distribute ASKA

19 May 2014 | News | By BioSpectrum Bureau

Takeda inks pact to distribute ASKA



Takeda has licensed the patent to Aska for the authorized generic drug. Aska has gained approval from the Ministry of Health, Labour and Welfare, and is currently applying for listing on the National Health Insurance (NHI) Price List for June 2014.

Although the complete terms of the agreement have not been disclosed, Aska will launch and promote the drug to healthcare professionals after it is listed on the NHI price list. Takeda will then purchase this drug from Aska, and distribute it to wholesalers. The launch of this drug will help expand Aska's product lineup and increase its presence in the generics pharma sector. This also provides the company with an opportunity to provide patients and healthcare professionals with an AG similar to Blopress.

Takeda has said that it recognizes the need for generic drugs while maintaining quality. The company will continue to explore potential business opportunities that will strengthen its position in the market.

It will also continue to collect clinical data results of Blopress with a focus on safety evaluation and provide this information to healthcare professionals.